Ibandronic acid Other names: Ibandronate sodium

Chemical formula: C₉H₂₃NO₇P₂  Molecular mass: 319.229 g/mol  PubChem compound: 60852

Therapeutic indications

Ibandronic acid is indicated for:

Tumour-induced hypercalcaemia

Population group: only adults (18 years old or older)

Treatment of tumour-induced hypercalcaemia with or without metastases.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of skeletal events in breast cancer and bone metastases

Population group: only adults (18 years old or older)

Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ibandronic acid is contraindicated in the following cases:

Hypocalcaemia

Hypocalcemia

Oesophageal stricture, oesophageal achalasia

at least one of
Stricture of esophagus
Achalasia of esophagus

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: BONDRONAT Concentrate for solution for infusion
Summary of Product Characteristics (SPC) 2019: BONDRONAT Film-coated tablets
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈